Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab

Eric Nudleman1 Department of Ophthalmology, Shiley Eye Center, University of California, San Diego, La Jolla, CA, USA

Jeremy D Wolfe2 Beaumont Eye Institute, Oakland University William Beaumont School of Medicine, Ann Arbor, MI, USA;3 Associated Retinal Consultants, Royal Oak, Ann Arbor, MI, USA

Maria A Woodward4 Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, MI, USA

Yoshihiro Yonekawa2 Beaumont Eye Institute, Oakland University William Beaumont School of Medicine, Ann Arbor, MI, USA;3 Associated Retinal Consultants, Royal Oak, Ann Arbor, MI, USA

George A Williams2 Beaumont Eye Institute, Oakland University William Beaumont School of Medicine, Ann Arbor, MI, USA;3 Associated Retinal Consultants, Royal Oak, Ann Arbor, MI, USA

Tarek S Hassan2 Beaumont Eye Institute, Oakland University William Beaumont School of Medicine, Ann Arbor, MI, USA;3 Associated Retinal Consultants, Royal Oak, Ann Arbor, MI, USACorrespondence[email protected]

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab

Citations (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date